Tests CD19-targeted T cells in adults with advanced lymphoma or leukemia

Who can take part

• PROCUREMENT
• Referred patients (or respective donors) will initially be consented for procurement of blood for generation of the transduced ATL. Eligibility criteria at this stage include:
• Diagnosis of recurrent B-cell lymphoma or leukemia (ALL or CLL), or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory aggressive B-cell lymphoma with a treatment plan that will include high dose therapy and autologous stem cell transplantation
• CD19-positive tumor (result can be pending at this time)
• Age <= 75 years. The first 3 patients treated on the study should be adults (>= 18 years)
• Hgb greater than or equal to 7.0 (can be a transfused value)
• If pheresis required to collect blood:
• Creatinine < 1.5 x upper limit normal
• AST <1.5 × upper limit normal
• PT and APTT <1.5 × upper limit normal
• Informed consent explained to, understood by and signed by patient/guardian (and donor, where applicable). Patient/guardian given copy of informed consent; TREATMENT
• Diagnosis of recurrent B-cell lymphoma leukemia (ALL or CLL), or newly diagnosed patients unable to receive or complete standard therapy OR diagnosis of relapsed/refractory aggressive B-cell lymphoma with a treatment plan that will include high dose therapy and autologous stem cell transplantation
• CD19-positive tumor
• Age <= 75 years. The first 3 patients treated on the study should be adults (>= 18 years)
• Bilirubin less than 3 times the upper limit of normal
• AST less than 5 times the upper limit of normal
• Estimated GFR > 50 mL/min
• Pulse oximetry of > 90% on room air
• Karnofsky or Lansky score of > 60%
• Recovered from acute toxic effects of prior chemotherapy at least one week before entering this study. PD1/PDL1 inhibitors will be allowed if medically indicated
• Available autologous or syngeneic activated peripheral blood T cell products (CD28ζ and CD28/CD137ζ) with more than or equal to 15% expression of CD19.CAR determined by flow cytometry
• Life expectancy of greater than 12 weeks
• Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom
• Patients or legal guardians must sign an informed consent indicating that they are aware this is a research study and have been told of its possible benefits and toxic side effects. Patients or their guardians will be given a copy of the consent form

Who cannot take part

• Currently receiving any investigational agents or received any tumor vaccines within the previous 6 weeks. (Note treatment with PD1/PDL1 inhibitors is allowed.)
• Active infection requiring antibiotics
• No history of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervix cancer) unless the tumor was successfully treated with curative intent at least 2 years before trial entry; TREATMENT
• History of hypersensitivity reactions to murine protein-containing products
• Active infection with HIV or HTLV
• PROCUREMENT
• Pregnant or lactating
• Tumor in a location where enlargement could cause airway obstruction